RxDoctor Payments DataLook up a doctor →

Donald Wurzburg, MD

Interventional Cardiology · Dallas, TXNPI 1457397598

Payments from drug & device makers

$341,343in general payments, 2019–2025

Across 385 payments — averaging $886.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Scientia Vascular$335K
  • Johnson & Johnson$2K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$716
  • Novartis$578
  • Abbott$535
  • Merck$532
  • plus $2K from 25 others

What the payments were for

  • Food & beverage$6,30396%
  • Education$2414%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$341,343 in reported general payments places this provider in the 90th percentile of 686 interventional cardiology providers in Texas.

See all interventional cardiology providers in Texas

Medicare billing

Part B allowed, 2024
$741,557
Medicare patients
1,606
Services billed
9,700

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban593$576,479
EntrestoSacubitril/Valsartan323$350,906
XareltoRivaroxaban238$218,892
FarxigaDapagliflozin Propanediol126$100,724
Repatha SureclickEvolocumab96$66,257
MultaqDronedarone Hcl39$48,869
JardianceEmpagliflozin45$34,994
VascepaIcosapent Ethyl52$27,270
BrilintaTicagrelor35$24,945
Praluent PenAlirocumab46$24,147
Icosapent Ethyl46$14,219
Metoprolol Succinate978$13,537
Rosuvastatin Calcium867$12,647
Isosorbide Dinitrate293$10,190
Atorvastatin Calcium1,026$9,334

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$255$576,479593 claims
NovartisEntresto$578$350,906323 claims
Johnson & JohnsonXarelto$1,985$218,892238 claims
AstraZenecaFarxiga, Brilinta$149$125,669161 claims
Sanofi-aventis U.S. LLCMultaq$370$48,86939 claims
Boehringer IngelheimJardiance$29$34,99445 claims
Esperion Therapeutics, Inc.Nexlizet$39$7,24412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 686 interventional cardiology providers in Texas.

Other interventional cardiology in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →